Vivoryon Therapeutics Powers a Breakthrough: $15M Investment Fuels Zucara’s Groundbreaking Hypoglycemia Therapy Revolution

We are thrilled to announce that Vivoryon Therapeutics N.V. has successfully raised €15,000,000 in a recent funding round to accelerate the groundbreaking development of ZT-01 by Zucara Therapeutics. This strategic investment represents a significant milestone in our journey to revolutionize diabetes care by addressing one of its most critical challenges—hypoglycemia. ZT-01 is a novel, first-in-class, once-daily therapeutic designed specifically for people with Type 1 diabetes and insulin-dependent Type 2 diabetes. By targeting the inhibition of somatostatin—a pancreatic hormone that hampers the glucagon response—ZT-01 aims to restore a natural glucagon secretion process and in turn prevent potentially dangerous hypoglycemic episodes. This infusion of capital will be instrumental in advancing ZT-01 through the essential stages of clinical development, ensuring rigorous evaluation of its safety and efficacy while expediting the transition from promising research to real-world therapeutic application. At a time when diabetes management is in urgent need of innovative solutions, Vivoryon Therapeutics’ support reinforces our commitment to improving patient outcomes and quality of life. The newly raised funds will bolster our research and development efforts, support comprehensive clinical trials, and help lay the foundations for eventual regulatory approval and commercialization. We are excited to work closely with our partners and stakeholders as we bring this transformative therapeutic option closer to those who need it most. For detailed information about our cutting-edge approach and ongoing progress, please visit www.zucara.ca. This funding announcement not only underscores our mission to redefine diabetes treatment but also marks a significant step forward in our commitment to patient-centric innovation.